Missing Script

Get updates

← All countries · Evidence Explorer

COUNTRY EXPLORER / SOUTH AMERICA / RESEARCH CHAPTER

Bolivia

Kallawaya healing knowledge, quinoa, Andean roots and the distance between tradition, laboratory promise and human benefit.

Evidence at a glance

Cancer: Bolivian medicinal-plant extracts and quinoa compounds have been tested against cancer cells. These experiments do not demonstrate that foods, herbs or extracts shrink tumors or improve survival in patients.

Metabolic health: Quinoa has randomized human dietary studies suggesting improvements in selected glucose and liver-fat measures. Yacon syrup has smaller, product-specific studies. Neither is an established treatment for diabetes or fatty-liver disease.

Altitude and chronic infection: Coca leaf has deep cultural significance but lacks strong clinical evidence for preventing altitude illness. Herbal remedies have not been shown to cure Chagas infection or its cardiac complications.

Scope: This chapter focuses on selected Bolivian and wider Andean practices. Many cited clinical trials were conducted outside Bolivia. Cultural documentation is not a clinical efficacy trial. Evidence checked October 28, 2026.

A living medical tradition—not a catalogue of products

The UNESCO description of the Kallawaya cosmovision documents a healing system from the Bautista Saavedra region north of La Paz, in which knowledge of plants, minerals, rituals, landscape and apprenticeship are intertwined. UNESCO recognized this as intangible cultural heritage in 2008. That recognition honors a community’s knowledge and practice; it does not certify particular remedies as effective cancer therapies.

A 2005 ethnobotanical survey (PMID 15707774) recorded medicinal uses for approximately 129 plant species sold in the markets of La Paz and El Alto, especially for digestive, musculoskeletal, urinary and gynecologic concerns. This is documentation of reported uses, not a controlled test of whether those treatments work. Market inventories cannot represent all Indigenous knowledge, much of which has its own custodians and rules of transmission.

Quinoa (Chenopodium quinoa) provides a different example: a food crop cultivated and preserved through Andean agricultural knowledge. FAO’s quinoa resource credits Indigenous Andean farmers with sustaining this food system. The plant also grows beyond Bolivia, so a trial conducted overseas is evidence about a formulation—not a study of Bolivian patients.

Cancer: the important line between a cell and a patient

Bolivian medicinal-plant extracts

A 2010 experimental study (DOI 10.5897/JMPR10.321) screened ethanolic extracts from 26 medicinal plant species associated with Bolivian traditional practice against Caco-2 colon cancer cells. Four extracts—Schkuhria pinnata, Piper longestylosum, Parastrephia lepidophylla and Erodium cicutarium—showed antiproliferative activity in the assay. The other 22 did not meet that reported activity criterion. This is preclinical evidence. Concentrated ethanol extracts are not equivalent to teas or whole plants, and no human tumor response, safe oncology dose or survival outcome was measured. The original article’s abstract was accessible for this appraisal; detailed extract exposures and toxicity thresholds were not independently verified.

Quinoa saponins: two experiments, different results

In a 2025 HT-29 colon-cancer cell study (DOI 10.1002/fsn3.4669), isolated quinoa saponins inhibited growth and altered cell-cycle and apoptosis markers in cultured cells. The experimental concentration of 40 μg/mL is not a human dose or a reason to take concentrated saponins.

A separate 2023 cell-line experiment (PMID 38146491) found that ethanolic extracts of white and red quinoa did not reduce viability in the tested lines, while selected isolated or synthetic sapogenins did. The findings are not identical interventions; importantly, they challenge any broad claim that eating quinoa directly kills cancer cells. No human anticancer efficacy trial of quinoa or these extracts was verified here.

Clinical meaning: Quinoa can be food in a varied diet if tolerated. Neither antioxidant assays nor cell death in a dish establishes prevention of recurrence, improved chemotherapy response or longer survival. People with cancer should not substitute these preparations for established treatment or nutrition support. See the site’s Cancer-Control Research evidence boundary.

Other chronic diseases: what human trials actually studied

Quinoa and impaired glucose tolerance

A 2025 randomized trial (DOI 10.1039/D4FO04557B) allocated 207 adults with impaired glucose tolerance in China to quinoa (100 g per day replacing part of their staple food), a multigrain diet or control, with one year of follow-up. The published abstract reports better measures of glucose exposure, insulin resistance and conversion toward normal tolerance in the quinoa group, while glycemic variability was not significantly different from control. These outcomes are encouraging but do not prove prevention of heart attacks, kidney failure or cancer. The full trial methods, attrition and effect confidence intervals were not fully appraised in this review, so the numerical interpretation is abstract-limited.

Quinoa and fatty-liver disease

A 2025 randomized Iranian study (DOI 10.3389/fnut.2025.1505183) assigned 46 people with nonalcoholic fatty-liver disease to replace grains at lunch with quinoa or retain their usual grain intake for 12 weeks. The primary liver-fat measure (controlled attenuation parameter) improved, as did LDL cholesterol and a marker of insulin resistance; liver enzymes, fasting glucose and other measured parameters showed no significant between-group improvement. Small size and short follow-up leave fibrosis progression, cirrhosis and clinical events unknown. This was not a Bolivian trial.

Yacon syrup and insulin resistance

Yacon (Smallanthus sonchifolius) is an Andean root containing fructooligosaccharides. A 2009 placebo-controlled 120-day study (PMID 19254816) of women with obesity and insulin resistance in Argentina reported lower weight and insulin-resistance measures with specific yacon-syrup preparations. Fasting glucose and most lipid measures were not improved; gastrointestinal tolerability depended on the fructooligosaccharide dose. A 2019 double-blind crossover experiment (PMID 31732062) in 40 women found lower glucose or insulin at certain short post-breakfast time points after 40 g of syrup compared with placebo. A two-hour glucose curve cannot establish diabetes reversal or cardiovascular protection.

Coca leaf and altitude symptoms

Coca leaves (Erythroxylum species) have distinct cultural and ceremonial roles in the Andes. According to the CDC Yellow Book (2026 edition, published April 23, 2025), coca tea or chewing has no strong evidence for preventing or treating altitude illness, and use may yield a positive cocaine-metabolite drug test. Legal status varies by jurisdiction. Acute altitude illness can worsen rapidly: ascent management and medical assessment matter more than any unproven tea.

Chagas disease and chronic heart health

Chagas disease, caused by Trypanosoma cruzi, can progress to cardiomyopathy and digestive disease. The WHO’s April 14, 2026 guidance identifies benznidazole and nifurtimox as antiparasitic treatments, particularly effective early in infection, while later disease requires individualized assessment and organ-specific care. No Kallawaya herb, coca product, quinoa extract or yacon preparation should be represented as a parasite cure or replacement for established care. This section concerns an important regional chronic-disease question, not a traditional-remedy trial.

Safety, interactions and uncertainty

  • During chemotherapy, immunotherapy or before surgery: disclose every botanical preparation and concentrated extract to the oncology team. An unstudied plant–drug interaction is not evidence of safety. Avoid interpreting an in-vitro concentration as an oral dose.
  • Yacon syrup: concentrated fructooligosaccharides may cause bloating, cramping or diarrhea. Study products differ from whole roots. People with diabetes or GI illness should discuss major diet changes with their care team.
  • Quinoa: ordinary washed and cooked grain is different from isolated saponin supplements. In the setting of unintentional weight loss, cancer cachexia, dysphagia or limited intake, individualized nutrition comes before experimental restrictions.
  • Coca leaf: consider drug screening, local laws and possible stimulant-related concerns; high-altitude symptoms require established evaluation and treatment. Do not infer safety in pregnancy or with cardiovascular drugs from cultural longevity of use.
  • Unverified mixtures: identity, purity, dosing, contamination and adverse-event reporting were not established for most traditional plant preparations in the cited literature.

Questions worth asking the care team

  • Is my goal symptom relief, better metabolic control or actual cancer control—and has that outcome been tested in people?
  • Is the product in a study the same species, extract and dose as what is being sold?
  • Could this affect my treatment, blood sugar, liver or kidney function, nutrition, or a required drug test?
  • If a practice is culturally important to me, how can it be incorporated without delaying effective medical care?

Educational information, not individual treatment advice. This is a selective, non-exhaustive appraisal of accessible sources as of October 28, 2026, not an independent clinician sign-off. A cultural tradition, a mechanism in a cell line and a human clinical outcome require different standards of evidence.

Primary sources and verification notes

← Explore another country · Evidence Explorer